Search research articles
Contact Us
Filters
Showing results (51-60 of 94) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
JTO Clinical and Research Reports
|
September 30, 2021
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i>-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
Julie R Brahmer, Melissa L Johnson, Manuel Cobo, et al.
The Lancet. Oncology
|
May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Byoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
The New England Journal of Medicine
|
October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
Melissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
JCO Precision Oncology
|
April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices
Makenzi Evangelist, Bo Wang, James E Butrynski, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 94) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
JTO Clinical and Research Reports
|
September 30, 2021
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i>-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
Julie R Brahmer, Melissa L Johnson, Manuel Cobo, et al.
The Lancet. Oncology
|
May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Byoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2025
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Conor E Steuer, Hidetoshi Hayashi, Wu-Chou Su, et al.
The New England Journal of Medicine
|
October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
Melissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
JCO Precision Oncology
|
April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices
Makenzi Evangelist, Bo Wang, James E Butrynski, et al.
Molecular Cancer Therapeutics
|
December 5, 2024
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Melissa L Johnson, Beni B Wolf, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Melissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Page
of 10